ZL-1310 is an innovative ADC targeting DLL3, a promising therapeutic target for small cell lung cancer and other DLL3s.+ solid tumor
Data will be shared in a poster presentation at the European Lung Cancer Conference 2024 (ELCC 2024).
Shanghai and Cambridge, Massachusetts, March 13, 2024–(BUSINESS WIRE)–Zylabo Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the completion of a preclinical study highlighting the therapeutic potential of ZL-1310, the company’s next-generation global antibody-drug conjugate. announced that the results would be announced. ADC) program. The preclinical profile of ZL-1310 will be the focus of a poster presentation at the European Lung Cancer Conference 2024 (ELCC 2024), scheduled to be held March 20-23, 2024 in Prague, Czech Republic.
ZL-1310 is a novel and promising ADC within Zai Lab’s global oncology R&D pipeline and is a proven therapeutic target for the treatment of small cell lung cancer (SCLC), delta-like ligand 3 (DLL3). ) is targeted. DLL3 is expressed on the cell surface of most SCLCs and plays a pivotal role in promoting SCLC cell proliferation, migration, and invasion.
“ZL-1310 has high affinity for its target DLL3, releasing its payload both intracellularly and into the tumor microenvironment, and also enables a bystander effect of camptothecin-derived payloads,” said President and General Manager. said Dr. Rafael G. Amado of Global Oncology Research and Development, Zai Lab “The promising preclinical data we will present at ELCC 2024 formed the basis for the Phase 1 clinical trial of ZL-1310, which began in January of this year.”
Data from preclinical IND validation studies shared at ELCC 2024 show that ZL-1310 exhibits strong and specific binding to DLL3 on the cell surface, leading to internalization, cell cycle arrest, and induction of apoptosis in tumor cells. It shows that. In vivo, ZL-1310 effectively inhibited the growth of established human tumors in both cancer cell-derived (CDX) and SCLC patient sample-derived (PDX) xenograft models in a dose-dependent manner.
ZL-1310 was discovered in MediLink Therapeutics’ proprietary TMALIN® platform. This is a next-generation ADC platform designed to exploit the tumor microenvironment to overcome the challenges of current ADC drugs. Zai Lab entered into a partnership and worldwide exclusive license agreement with MediLink in April 2023. Subsequently, in January 2024, Zai Lab initiated a global Phase 1 trial of ZL-1310 in patients with relapsed/refractory SCLC who have progressed after platinum-based therapy.
Details of poster presentations at ELCC 2024 are as follows.
title: Development and characterization of novel DLL3-targeted antibody-drug conjugates (ADCs) for solid tumor therapy
Presenter: Linda N Liu, Senior Vice President, Biologics Discovery, Zai Lab
Date Time: Friday, March 22, 2024, 12:00pm – 12:45pm CET
position: Prague Congress Center, Congress Hall Foyer
About small cell lung cancer (SCLC) and neuroendocrine tumors
SCLC and neuroendocrine tumors are diseases with significant unmet medical need worldwide. The annual incidence of SCLC is over 300,000 cases worldwide.1 More than 88% of SCLC patients overexpress DLL3 and could benefit from targeted therapeutics.2 Furthermore, DLL3 is a promising target that is highly expressed in several tumors with neuroendocrine features. There are approximately 171,000 people in the United States with neuroendocrine tumors, and that number continues to grow, but treatment options remain limited.3
About Zai Lab
Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. The Company is focused on discovering, developing and commercializing innovative products that address disease states with significant unmet needs in oncology, autoimmune diseases, infectious diseases and neuroscience. Our goal is to leverage our capabilities and resources to positively impact the health of people in China and around the world.
For more information about Zai Lab, visit www.zailaboratory.com or follow us below. www.twitter.com/ZaiLab_Global.
Zai Lab’s forward-looking statements
This press release contains forward-looking statements regarding our future expectations, plans and prospects for Zai Lab. This includes, but is not limited to, statements regarding prospects and plans regarding the development and commercialization of next-generation ADCs, including ZL-1310. We discuss the benefits of ZL-1310 and its potential treatment for SCLC and neuroendocrine tumors. These forward-looking statements include “aims,” ”anticipates,” “believes,” “may,” “estimates,” “expects,” “predicts,” “goals,” “intends,” It may include words such as “will” and “may.” “plan,” “potential,” “potential,” “plan,” “would,” and other similar expressions. Such statements constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical fact or guarantees or guarantees of future performance. Forward-looking statements are based on the Company’s expectations and assumptions as of the date of this press release and are subject to inherent uncertainties that may cause them to differ materially from those contemplated in the forward-looking statements; may be subject to risks and changes in circumstances. Actual results will be the result of a variety of important factors, including, but not limited to: (1) our ability to successfully commercialize and generate revenue from our approved products; (2) our ability to obtain approved products; Results may differ materially from those indicated in such forward-looking statements. funding for our operations and business initiatives; (3) the results of clinical and preclinical development of our product candidates; and (4) the nature of decisions made by relevant regulatory authorities regarding regulatory approval of our product candidates. and timing, (5) risks associated with our business activities in China, and (6) our most recent annual and quarterly reports and other reports filed by us with the Securities and Exchange Commission (SEC). Other factors identified in the book. We expect that our expectations and assumptions may change as a result of subsequent events and developments, and, unless necessary, our expectations and assumptions may change as a result of new information, future events or otherwise. We undertake no obligation to update or revise any forward-looking statements. By law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Our SEC filings are available at: www.zailaboratory.com On the SEC website: www.sec.gov.
reference:
1. Globokan 2020
2. Orgilmma Regzedmma et al. 2019, Onco Targets and Treatments
3. Neuroendocrine tumor statistics on Cancer.Net [ASCO Knowledge Conquers Cancer]
View source version on businesswire.com. https://www.businesswire.com/news/home/20240313685689/ja/
contact address
For more information, please contact us below.
Public relations activities for investors:
Christine Chiou / Lina Chan
+1 (917) 886-6929 / +86 136 8257 6943
christine.chiou1@zailaboratory.com / lina.zhang@zailaboratory.com
media:
Jennifer Cheung / Xiaoyu Chen
+1 (857) 270-8985 / +86 185 0015 5011
jennifer.chang@zailaboratory.com / xiaoyu.chen@zailaboratory.com
